AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05960110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoride varnish
Description: Fluoride varnish 26200 ppm
Study NCT05960110 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Fluoride toothpaste
Description: Fluoride toothpaste 1450 ppm
Study NCT03038802 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic hepatitis B vaccine
Description: HBV vaccine based on unique combination of recombinant PreS hepatitis B surface antigen particles formulated with Advax-2 adjuvant
Study NCT05515328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [¹⁴C] BI 685509 formulation 1
Description: \[¹⁴C\] BI 685509 formulation 1
Study NCT03038802 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Commercial Hepatitis B vaccine
Description: Commercially available prophylactic hepatitis B vaccine formulated with alum adjuvant
Study NCT05515328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [¹⁴C] BI 685509 formulation 2
Description: \[¹⁴C\] BI 685509 formulation 2
Study NCT05515328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 685509 formulation 3
Description: BI 685509 formulation 3
Study NCT06396572 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IVR-Procedure
Description: Using immersive virtual reality to learn urinary catheterisation procedure
Study NCT06396572 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nursing Clinical Laboratory practice
Description: Using nursing clinical laboratory sessions to learn urinary catheterisation procedure
Study NCT06152419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Patients will be asked to complete questionnaires to evaluate the quality and the impact of the video and to assess the need for additional information.
Study NCT04715256 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive assessment of obsessive-compulsive and impulsive behaviours
Description: The content of the assessment will be the same for all subjects and will consist of a cognitive assessment (attention, impulsivity) and a clinical assessment (impulsive behaviour, autistic traits,obsessive-compulsive behaviour).
Study NCT04842500 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Demand Informed Moderator Analysis
Description: This analysis is designed to determine the degree to which relative price, and the timing of extinction, interact to increase or abate responding during extinction (thereby highlighting mechanisms of control).
Study NCT05335993 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oregovomab
Description: 2 mg, added to 50 mL of Sodium Chloride infused over 20 ± 5 minutes.
Study NCT05335993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: 300mg administered orally once daily starting at the first day of treatment (Day 1 Week 1) to the end of Week 12. Subjects whose baseline weight is \<77 kg or platelet count is \<150,000 μL, the daily dosing will be 200mg.
Study NCT04795908 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: rTMS will be delivered using a MagStim Super Rapid2 TMS therapy system.
Study NCT04795908 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive behavioral intervention
Description: Patients will receive CBIT with a therapist trained in CBIT. Each session will last about an hour and will be delivered remotely via telemedicine. Sessions will be tailed to the patient's individual needs.
Study NCT05077436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamifeport Formulation 1
Description: Vamifeport Formulation 1 is available as 60 mg oral capsules
Study NCT05077436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamifeport Formulation 2
Description: Vamifeport Formulation 2 is available as 60 mg oral capsules
Study NCT04715256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive assessment of obsessive-compulsive and impulsive behaviours
Description: The content of the assessment will be the same for all subjects and will consist of a cognitive assessment (attention, impulsivity) and a clinical assessment (impulsive behaviour, autistic traits,obsessive-compulsive behaviour).
Study NCT04715256 — intervention group
Intervention type: GENETIC
Group type: SHAM_COMPARATOR
Intervention: Genomic analysis
Description: A genome-wide association study (GWAS) will be performed for all subjects to search for associations between KCNQ1 mutations, insulin regulation and psychological features.
Study NCT04970446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: All patients will receive a one week course of antibiotic therapy.
Study NCT04970446 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antibiotics
Description: All patients will receive a one week course of antibiotic therapy.
Study NCT04970446 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietician designed diet
Description: All patients will be recommended dietary modification 3 weeks prior to, and during, the study.
Study NCT04970446 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietician designed diet
Description: All patients will be recommended dietary modification 3 weeks prior to, and during, the study.
Study NCT04970446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FMT
Description: Anaerobically prepared stool. Dosing will vary according to mode of administration.
Study NCT04970446 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will contain food colourant, 0.9% normal saline and glycerol.
Study NCT06217692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nutrition education
Description: nutrition education
Study NCT04715256 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genomic analysis
Description: A genome-wide association study (GWAS) will be performed for all subjects to search for associations between KCNQ1 mutations, insulin regulation and psychological features.
Study NCT04715256 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Glucoregulation assessment
Description: Fasted glycaemia and insulinaemia, glycated haemoglobin (HbA1c) and glycaemia following an oral glucose challenge test will be measured in all study subjects.
Study NCT04715256 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Glucoregulation assessment
Description: Fasted glycaemia and insulinaemia, glycated haemoglobin (HbA1c) and glycaemia following an oral glucose challenge test will be measured in all study subjects.
Study NCT04961918 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL)
Description: Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL)
Study NCT05474807 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered strengths use intervention
Description: The online strengths use intervention program, will be based on Miglianico et al.'s (2020) general framework, following the theorized five stages: (1) preparation and commitment, (2) identification, (3) integration, (4) action, and (5) evaluation.~As to increase participant engagement and motivation, gamification components will be embedded in several of these stages.~The entire intervention will be delivered online via an LMS software solution.
Study NCT06015412 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Radiographic classification
Description: disease stages ranged from 1 to 4 according to the Kellgren-Lawrence radiographic classification system
Study NCT06553846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium [177Lu]-FAP-75
Description: Lutetium \[177Lu\]-FAP-75 will be administrated per dose level in which the patients are assigned.
Study NCT06330285 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-learning
Description: CPET (Cardiopulmonary exercise test) e-learning application The content, planning and design of 4 lessons are as follows:~1. Introduction and CPET Fundamentals:~2. Respiratory function tests~3. Field Field Tests and CPET Results~4. Problems and examples
Study NCT06330285 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: face to face learning
Description: CPET (Cardiopulmonary exercise test) face to face education. The content, planning and design of 4 lessons are as follows:~Contents:~1. Introduction and CPET Fundamentals:~2. Respiratory function tests~3. Field Field Tests and CPET Results~4. Problems and examples
Study NCT05519618 — intervention group
Intervention type: PROCEDURE
Intervention: Epidural veins pressure and flow measurement
Description: The purpose of this study is to measure to pressure and flow of epidural venous plexus.~The procedure will be performed alongside during pre-operative embolization at the angiography suite.~It will be performed under general anesthesia. A the start of the procedure, a venous access will be established at the inguinal region. Co-axial catheters will be navigated to epidural venous plexus under the guidance of fluoroscopy. After the placement of catheter, the pressure and flow of epidural venous plexus will be measured at three time points: 1. Right after catheter reach the targeted location 2. Right before embolization. 3. After embolization. The participant will be instructed to control their breathe during measurement.~After measurement, the catheter will be removed alongside with embolization devices, and achieved hemostasis as routine.
Study NCT05035823 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Motor Neuroprosthesis (MNP)
Description: Type of implantable brain computer interface
Study NCT04702048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection
Description: Patients randomized to Arm A will receive 2 mg IVT aflibercept injections every 4 weeks (Q4W) to Week 20, followed by 2-mg aflibercept injections Q8W to Week 52.
Study NCT04702048 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sham injection
Description: Patients randomized to Arm B will receive sham intravitreal injections every 4 weeks (Q4W) to Week 20, followed by sham intravitreal injections Q8W to Week 52. Sham means eye will be numbed and a syringe with no needle will be touched to the eye.
Study NCT05052528 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chimeric Antigen Receptor T-Cell Therapy
Description: Given CD19 CAR T cells IV
Study NCT05052528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT05161650 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone monoester (3-OHB)
Description: Commercially available ketone supplement
Study NCT05161650 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo drink
Description: Isocaloric placebo
Study NCT05114837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allogeneic CAR19 regulatory T cells (CAR19-tTreg)
Description: A single dose administration of CAR19-tTreg
Study NCT05114837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/m\^2 is administered as an intravenous (IV) infusion per institutional guidelines once a day on 4 consecutive days (Day -5, Day -4, Day -3 and Day -2)
Study NCT05114837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 500 mg/m\^2 is administered as an IV infusion per institutional guidelines once a day on 2 consecutive days (Day -5, and Day -4)
Study NCT05596721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Treat patient with azithromycin for 12w.
Study NCT05596721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICS/LABA
Description: Treat patient with ICS/LABA according to Global Initiative for Asthma (GINA) guideline.
Study NCT05596721 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ICS/LABA
Description: Treat patient with ICS/LABA according to Global Initiative for Asthma (GINA) guideline.
Study NCT05369286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAX-40279-01 and Toripalimab
Description: MAX-40279-01combined with Toripalimab
Study NCT06397820 — intervention group
Intervention type: DEVICE
Intervention: Percutaneous coronary intervention (PCI)
Description: Revascularization by percutaneous coronary intervention for vessels with decreased PET-derived flow indexes
Study NCT05886439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LK101 injection (personlized neoantigen pulsed DC vaccine )
Description: LK101 will be administered in a prime-boost schedule of 4 priming vaccination followed by 3 booster vaccinations.
Study NCT05886439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will receive pembrolizumab(200mg IV) Q3W until disease progression (PD), intolerable toxicity.
Study NCT05886439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Patients will receive durvalumab (1500mg IV) Q3W until disease progression (PD), intolerable toxicity.
Study NCT04802707 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: deoxycytidine and deoxythymidine
Description: The Investigational Product (IP) dC/dT100-400 will be administered orally every day (QD) and the dose is divided over 3 taking/day for the daily dose of 100 mg/kg from Day 1-7, 200 mg/kg from Day 8-14, 300 mg/kg from Day 15- 21 and 400 mg/kg from Day 22 to 730. Doses was chosen according to the safety and efficacy doses used in the literature.
Study NCT05415774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1 : S-C1-C2
Description: Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2
Study NCT05415774 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1 : S-C1-C2
Description: Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2
Study NCT05415774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2 : S-C2-C1
Description: Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2
Study NCT05415774 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2 : S-C2-C1
Description: Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2
Study NCT05415774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3 : C1 - S - C2
Description: Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2
Study NCT05076292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GlucaGen
Description: 150 ug or 75\*2 ug glucagon will be administered subcutaneously to the participants before and after exercise.
Study NCT05076292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Saline will be used as placebo before and after exercise.
Study NCT05415774 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3 : C1 - S - C2
Description: Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2
Study NCT05415774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4 : C1 -C2 - S
Description: Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2
Study NCT04456946 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy
Description: Low Level Laser Therapy
Study NCT04456946 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occlusal Splint Treatment
Description: Occlusal Splint Treatment
Study NCT06557746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coca-Cola
Description: 100 ml Coca-Cola every 30 minutes during the operation
Study NCT06557746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen
Description: Continuous supply of oxygen (2 L/min) during the operation
Study NCT05415774 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 4 : C1 -C2 - S
Description: Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2
Study NCT05052528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT05415774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5 : C2 - S - C1
Description: Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2
Study NCT05415774 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 5 : C2 - S - C1
Description: Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2
Study NCT05415774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 6 : C2 - C1 - S
Description: Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2
Study NCT05415774 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 6 : C2 - C1 - S
Description: Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2
Study NCT05052528 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT04954534 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human umbilical cord blood derived mesenchymal stem cells
Description: High dose: 3 x 10\^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4-week intervals
Study NCT05065593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistance and aerobic exercise
Description: Resistive exercises allow loading the muscle under suitable conditions with various weights or resistances. In order to increase the level of physical fitness with the increase of muscle strength and bone mass in individuals, resistance exercises were preferred. Aerobic exercises, on the other hand, are a special type of exercise that develops both the musculoskeletal system and the cardiovascular system, which includes large muscle groups and should be performed for at least 20 minutes when the heart rate accelerates at certain rates. Aerobic exercise was preferred in order to increase cardiovascular endurance, accelerate fat burning and reduce fatigue.
Study NCT05065593 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical activity recommendation
Description: Patients will be informed about the importance of lifestyle change in disease management, walking training will be given to increase their physical activity level, and participants will be asked to follow a 45-minute walking program every day within their own means.
Study NCT06179680 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: MRI Protocol: Uses advanced MRI sequences to examine brain structures and detect white matter issues.~WMH Assessment: Evaluates white matter health using various methods, including manual and automated tools.~Neuropsychological Testing: Subjects undergo comprehensive cognitive testing administered by IRCCS Policlinico San Donato's Clinical Psychology Service.~Follow-up: Patients are monitored for cognitive changes semiannually, with additional assessments for those showing signs of progression. After two years, all patients undergo examination and tests to assess their condition.
Study NCT05575622 — intervention group
Intervention type: DEVICE
Intervention: CTC PD-L1, exosomal PD-L1, and exosomal LAG-3 detection
Description: Collect peripheral blood sample of 200 HCC patients at treatment baseline, every time point response till disease progression.Blood samples will be transferred to central lab to detect CTC PD-L1, exosomal PD-L1, and exosomal LAG-3 by microfluidic chip.Tumor response evaluation will be performed after two cycles of therapy by CT/MRI based on RECIST.Clinical data, including tumor stage,metastatic organ ,regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.